KR100771752B1 - 항암 예방접종용 항체의 용도 - Google Patents

항암 예방접종용 항체의 용도 Download PDF

Info

Publication number
KR100771752B1
KR100771752B1 KR1020017008697A KR20017008697A KR100771752B1 KR 100771752 B1 KR100771752 B1 KR 100771752B1 KR 1020017008697 A KR1020017008697 A KR 1020017008697A KR 20017008697 A KR20017008697 A KR 20017008697A KR 100771752 B1 KR100771752 B1 KR 100771752B1
Authority
KR
South Korea
Prior art keywords
antibody
vaccination
antibodies
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017008697A
Other languages
English (en)
Korean (ko)
Other versions
KR20010101446A (ko
Inventor
엑커트헬무트
로이브너한스
Original Assignee
이게네온 크렙스-이문테라피 포르슝스-운트 엔트뷔클룽스-아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이게네온 크렙스-이문테라피 포르슝스-운트 엔트뷔클룽스-아게 filed Critical 이게네온 크렙스-이문테라피 포르슝스-운트 엔트뷔클룽스-아게
Publication of KR20010101446A publication Critical patent/KR20010101446A/ko
Application granted granted Critical
Publication of KR100771752B1 publication Critical patent/KR100771752B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020017008697A 1999-01-13 2000-01-12 항암 예방접종용 항체의 용도 Expired - Fee Related KR100771752B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH51/99 1999-01-13
CH5199 1999-01-13

Publications (2)

Publication Number Publication Date
KR20010101446A KR20010101446A (ko) 2001-11-14
KR100771752B1 true KR100771752B1 (ko) 2007-10-30

Family

ID=4178206

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017008697A Expired - Fee Related KR100771752B1 (ko) 1999-01-13 2000-01-12 항암 예방접종용 항체의 용도

Country Status (28)

Country Link
US (3) US7691372B2 (enExample)
EP (2) EP1230932B1 (enExample)
JP (1) JP4774551B2 (enExample)
KR (1) KR100771752B1 (enExample)
CN (1) CN1188169C (enExample)
AT (2) ATE286745T1 (enExample)
AU (1) AU768515B2 (enExample)
CA (1) CA2360382C (enExample)
CZ (1) CZ302801B6 (enExample)
DE (2) DE50000243D1 (enExample)
DK (2) DK1230932T3 (enExample)
EE (1) EE05474B1 (enExample)
ES (2) ES2177509T3 (enExample)
HK (1) HK1044487B (enExample)
HR (1) HRP20010526A2 (enExample)
HU (1) HU226150B1 (enExample)
ID (1) ID30223A (enExample)
IL (2) IL144265A0 (enExample)
IS (1) IS5998A (enExample)
MX (1) MXPA01007148A (enExample)
NO (1) NO329917B1 (enExample)
NZ (1) NZ512722A (enExample)
PL (1) PL201533B1 (enExample)
PT (2) PT1230932E (enExample)
SI (2) SI1230932T1 (enExample)
SK (1) SK286627B6 (enExample)
TR (1) TR200102034T2 (enExample)
WO (1) WO2000041722A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230932B1 (de) * 1999-01-13 2005-01-12 Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG Verwendung von Antikörpern zur Vakzinierung gegen Krebs
AT410172B (de) * 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2006005367A1 (en) 2004-07-14 2006-01-19 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
EP1618890B1 (en) * 2004-07-20 2010-10-06 Altropus Gmbh Use of antibodies in a very low dose for the vaccination against cancer
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
EP2217253B1 (en) 2007-12-07 2011-06-29 N.V. Nutricia Bifidobacterium for dust mite allergy
MX2011007049A (es) 2009-02-24 2011-08-03 Esbatech Alcon Biomed Res Unit Metodos para identificar inmunoligadores de los antegenos de la superficie celular.
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056416A1 (en) * 1997-06-09 1998-12-17 Yeda Research And Development Co. Ltd. Immunogenic compositions for induction of anti-tumor immunity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
EP0857176A1 (en) * 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
ATE480566T1 (de) * 1998-06-15 2010-09-15 Quest Pharmatech Inc Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
EP1230932B1 (de) * 1999-01-13 2005-01-12 Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG Verwendung von Antikörpern zur Vakzinierung gegen Krebs
AU2001261371A1 (en) 2000-05-16 2001-11-26 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions containing same and method for using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056416A1 (en) * 1997-06-09 1998-12-17 Yeda Research And Development Co. Ltd. Immunogenic compositions for induction of anti-tumor immunity

Also Published As

Publication number Publication date
ATE219687T1 (de) 2002-07-15
US20120003232A1 (en) 2012-01-05
IL144265A (en) 2006-08-20
AU768515B2 (en) 2003-12-18
KR20010101446A (ko) 2001-11-14
ES2177509T3 (es) 2002-12-16
SI1140168T1 (en) 2002-10-31
HRP20010526A2 (en) 2002-08-31
HK1044487A1 (en) 2002-10-25
PL201533B1 (pl) 2009-04-30
EP1140168A1 (de) 2001-10-10
CN1344167A (zh) 2002-04-10
WO2000041722A1 (de) 2000-07-20
CN1188169C (zh) 2005-02-09
TR200102034T2 (tr) 2001-11-21
US20070224202A1 (en) 2007-09-27
EP1230932B1 (de) 2005-01-12
PL364747A1 (en) 2004-12-13
CA2360382A1 (en) 2000-07-20
CA2360382C (en) 2011-05-24
EE05474B1 (et) 2011-10-17
DE50009240D1 (de) 2005-02-17
JP2002534481A (ja) 2002-10-15
SK9642001A3 (en) 2002-03-05
PT1140168E (pt) 2002-11-29
NO329917B1 (no) 2011-01-24
HU226150B1 (en) 2008-05-28
DK1230932T3 (da) 2005-04-25
US20100233178A1 (en) 2010-09-16
US8444974B2 (en) 2013-05-21
HUP0200527A2 (en) 2002-06-29
NZ512722A (en) 2003-07-25
DK1140168T3 (da) 2002-09-30
DE50000243D1 (de) 2002-08-01
NO20013093D0 (no) 2001-06-21
ATE286745T1 (de) 2005-01-15
AU2796400A (en) 2000-08-01
JP4774551B2 (ja) 2011-09-14
CZ302801B6 (cs) 2011-11-16
EP1140168B1 (de) 2002-06-26
ES2236375T3 (es) 2005-07-16
SI1230932T1 (en) 2005-06-30
US7691372B2 (en) 2010-04-06
EP1230932A3 (de) 2003-11-26
EE200100366A (et) 2002-10-15
CZ20012581A3 (cs) 2002-01-16
IL144265A0 (en) 2002-05-23
MXPA01007148A (es) 2002-03-27
SK286627B6 (sk) 2009-02-05
IS5998A (is) 2001-07-10
EP1230932A2 (de) 2002-08-14
PT1230932E (pt) 2005-04-29
ID30223A (id) 2001-11-15
HK1044487B (zh) 2005-09-16
NO20013093L (no) 2001-09-10

Similar Documents

Publication Publication Date Title
US8444974B2 (en) Use of antibodies for the vaccination against cancer
EP1241264A1 (en) Monoclonal antibodies to colon cancer antigen
JP3565351B2 (ja) 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物
US9487567B2 (en) Method for the production of an immunostimulating mucin (MUC1)
AU780853B2 (en) Use of anti-idiotypical antibodies as vaccines against cancer
US20040265318A1 (en) Use of antibodies for the vaccination against cancer
EP1618890B1 (en) Use of antibodies in a very low dose for the vaccination against cancer
KR100372958B1 (ko) 면역반응을개시시키기위해다중에피토프항원의입체형태를변화시키기위한방법및조성물
MXPA98009586A (en) Method and composition for the reconformation of multi-peptide antigens to start an animal response

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20110915

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20120927

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20131025

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20131025